GNLX Genelux (GNLX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001231457
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
32
13F, latest reported quarter
What the filings say about GNLX
Insiders, 180 days
-$237.3K net sold
6 sellers · 0% of sales under a 10b5-1 plan
Genelux insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, GENELUX Corp insiders sold a net $237.3K of stock across 149 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Aug 4, 2026.
- The trade is 3.2% of the 318,480 shares held after it.
- 2 other insiders sold within 30 days.
- 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technical Officer Cappello Joseph sold about $28.1K of GNLX on Aug 31, 2026; 2 other insiders sold within 30 days and 32 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Aug 4, 2026.
- The trade is 2.8% of the 1,226,427 shares held after it.
- 2 other insiders sold within 30 days.
- 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Zindrick Thomas sold about $91.9K of GNLX on Aug 31, 2026, the largest insider sale at the company since 2024; 2 other insiders sold within 30 days and 32 funds added in the latest 13F quarter.Context
- 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Aug 4, 2026.
- The trade is 3.7% of the 258,688 shares held after it.
- 2 other insiders sold within 30 days.
- 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Yu Yong sold about $26.7K of GNLX on Aug 31, 2026; 2 other insiders sold within 30 days and 32 funds added in the latest 13F quarter.Context
- 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on May 11, 2026.
- The trade is 0.2% of the 268,371 shares held after it.
- 2 other insiders sold within 30 days.
- 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Yu Yong sold about $1.9K of GNLX on Aug 4, 2026; 2 other insiders sold within 30 days and 32 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 11, 2026.
- The trade is 0.2% of the 328,737 shares held after it.
- 2 other insiders sold within 30 days.
- 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technical Officer Cappello Joseph sold about $1.9K of GNLX on Aug 4, 2026; 2 other insiders sold within 30 days and 32 funds added in the latest 13F quarter.149 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$237.3K over 180 days
-$159.4K over 90 days
more than 51% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
32 funds bought in last quarter
below 61% of Pharma & Biotech
Revenue
+0.0% year over year
below 56% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
12.0% of the float short (float per yahoo 2026-10-26) · 20.4 days to cover · settled 2026-09-30
more than 70% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch GNLX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-75.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GNLX: institutional holders (13F)
13F holdings, latest reported quarter
2,262,108 sh
$6.8M
1,677,724 sh
$5.0M
1,380,666 sh
$4.2M
439,602 sh
$1.3M
439,213 sh
$1.3M
Congress trades in GNLX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GNLX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JOHN SMITHER
Filed 2026-07-01
$34.9K
GNLX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$415.5K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$28.0K position · as of 2026-06-30
0.0%
Victory Extended Market Index Fund
$13.6K position · as of 2026-07-31
0.0%
Goldman Sachs Absolute Return Tracker Fund
$103.3K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$643.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$1.4M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
1 active
1
Phase 3
1 active
1
Not applicable
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $237.3K sold by insiders over 180 days, 32 funds added last quarter. Each figure is a federal filing, dated the day it went public.
GNLX financials
Revenue growth
0.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$8.0K
four quarters, 2024-01-01 to 2024-12-31
Revenue, TTM GNLX
| FY Dec 2025 | $8.0K |
| FY Dec 2024 | $8.0K |
| FY Dec 2023 | $170.0K |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM GNLX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$28.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM GNLX
| FY Dec 2025 | -$26.4M |
| FY Dec 2024 | -$21.6M |
| FY Dec 2023 | -$21.3M |
| FY Dec 2022 | -$3.6M |
| Jun 2026 | -$8.0M |
| Mar 2026 | -$7.0M |
| Dec 2025 | -$6.6M |
| Sep 2025 | -$7.1M |
| Jun 2025 | -$7.2M |
| Mar 2025 | -$5.5M |
| Dec 2024 | -$4.4M |
| Sep 2024 | -$5.8M |
At each fiscal year end
Single quarter
Debt to equity
0.58x
long-term 2022-12-31 (42 months older than the period end) plus current 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity GNLX
| FY Dec 2025 | 0.82x |
| FY Dec 2024 | 0.36x |
| FY Dec 2023 | 0.48x |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.58x |
| Mar 2026 | 0.41x |
| Dec 2025 | 0.82x |
| Sep 2025 | 0.51x |
| Jun 2025 | 0.39x |
| Mar 2025 | 0.32x |
| Dec 2024 | 0.36x |
| Sep 2024 | 0.28x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.68x
TTM operating cash flow over long-term 2022-12-31 (42 months older than the period end) plus current 2023-12-31 (30 months older than the period end)
Cash flow to debt GNLX
| FY Dec 2025 | -2.68x |
| FY Dec 2024 | -2.25x |
| FY Dec 2023 | -2.15x |
| FY Dec 2022 | -0.42x |
| Jun 2026 | -2.68x |
| Mar 2026 | -2.75x |
| Dec 2025 | -2.68x |
| Sep 2025 | -2.48x |
| Jun 2025 | -2.39x |
| Mar 2025 | -2.37x |
| Dec 2024 | -2.25x |
| Sep 2024 | -2.53x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-177.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity GNLX
| FY Dec 2025 | -170.0% |
| FY Dec 2024 | -130.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -177.9% |
| Mar 2026 | -127.3% |
| Dec 2025 | -170.0% |
| Sep 2025 | -123.3% |
| Jun 2025 | -98.7% |
| Mar 2025 | -131.4% |
| Dec 2024 | -130.6% |
| Sep 2024 | -96.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-121.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets GNLX
| FY Dec 2025 | -119.6% |
| FY Dec 2024 | -95.4% |
| FY Dec 2023 | -169.3% |
| FY Dec 2022 | -94.1% |
| Jun 2026 | -121.8% |
| Mar 2026 | -94.1% |
| Dec 2025 | -119.6% |
| Sep 2025 | -97.7% |
| Jun 2025 | -78.5% |
| Mar 2025 | -92.7% |
| Dec 2024 | -95.4% |
| Sep 2024 | -74.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital GNLX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-167.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed GNLX
| FY Dec 2025 | -163.6% |
| FY Dec 2024 | -129.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | -167.6% |
| Mar 2026 | -122.6% |
| Dec 2025 | -163.6% |
| Sep 2025 | -122.9% |
| Jun 2025 | -99.9% |
| Mar 2025 | -130.4% |
| Dec 2024 | -129.0% |
| Sep 2024 | -96.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing GNLX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$86.7M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term 2022-12-31 (42 months older than the period end) plus current 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value GNLX
| FY Dec 2025 | $170.0M |
| FY Dec 2024 | $82.4M |
| FY Dec 2023 | $374.3M |
| FY Dec 2022 | n/a |
| Jun 2026 | $135.2M |
| Mar 2026 | $108.6M |
| Dec 2025 | $170.0M |
| Sep 2025 | $161.5M |
| Jun 2025 | $111.2M |
| Mar 2025 | $86.6M |
| Dec 2024 | $82.4M |
| Sep 2024 | $85.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-33.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield GNLX
| FY Dec 2025 | -15.9% |
| FY Dec 2024 | -26.5% |
| FY Dec 2023 | -5.7% |
| FY Dec 2022 | n/a |
| Jun 2026 | -21.3% |
| Mar 2026 | -25.7% |
| Dec 2025 | -15.9% |
| Sep 2025 | -15.2% |
| Jun 2025 | -21.1% |
| Mar 2025 | -24.3% |
| Dec 2024 | -26.5% |
| Sep 2024 | -29.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing GNLX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $8.0K | $8.0K | $170.0K | $11.1M |
| Operating income | -$33.2M | -$31.7M | -$24.2M | -$3.0M |
| Net income | -$32.1M | -$29.9M | -$28.3M | -$5.2M |
| EPS (diluted) | -0.86 | -0.95 | -1.16 | -0.57 |
| Operating cash flow | -$25.3M | -$21.2M | -$20.3M | -$3.6M |
| Cash | $5.3M | $8.6M | $9.4M | $397.0K |
| Long-term debt | n/a | n/a | n/a | $8.5M |
SEC XBRL, fiscal years, as known on 2026-10-28
GNLX Stock Sonar score 6/7 axes
Find similar shapesCompareGNLX ranks highest on risk and compliance (53rd percentile) and growth (44th), and lowest on profitability (17th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
GNLX filings, in plain words
Are Genelux insiders buying or selling GNLX?
In the 180 days to 2026-10-28, Genelux insiders were net sellers, a net $237.3K across purchases and sales reported on Form 4, by 6 sellers.
Read the full summary
In the 180 days to 2026-10-28, Genelux insiders were net sellers of GNLX, a net $237.3K across purchases and sales reported on Form 4 by 6 sellers. None of the 13 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
